FTO.nl maakt op haar websites gebruik van cookies. Een cookie is een klein bestandje dat met een pagina van een website wordt meegestuurd en door uw browser (tijdelijk) op de harde schrijf van uw computer of mobiele apparatuur wordt opgeslagen.
Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
Ragland DR, Brand RJ. Coronary heart disease mortality in the Western Collaborative Group Study. Follow-up experience of 22 years. Am J Epidemiol 1988;127:462-475.
Seven Countries Study. Seven Countries Study | The first study to relate diet with cardiovascular disease. https://www.sevencountriesstudy.com/. Geraadpleegd april, 2024.
Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
Collaborators CTT (CTT). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012;380:581-590.
Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. The Lancet 2017;389:1730-1739.
Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk | European Heart Journal | Oxford Academic. Eur Heart J 2019;41:111-188.
Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis 2017;16:132.
Soliman GA. Dietary Cholesterol and the Lack of Evidence in Cardiovascular Disease. Nutrients 2018;10.
Ros E, Martínez-González MA, Estruch R, et al. Mediterranean diet and cardiovascular health: Teachings of the PREDIMED study. Adv Nutr Bethesda Md 2014;5:330S-6S.
Brouwers JRBJ, Roeters van Lennep JE, Maas AHEM. Rode gist rijst al cholesterolvervangervervanger? Een waarschuwing is op zijn plaats. Ned Tijdschr Geneeskd 2016;160:D99.
Commissie. (2022). Verordening (EU) 2022/860 van de Commissie van 1 juni 2022 tot wijziging van bijlage III bij Verordening (EG) nr. 1925/2006 van het Europees Parlement en de Raad wat betreft monacolinen uit rodegistrijst (Voor de EER relevante tekst). Publicatieblad van de Europese Unie, L (151), 37–41. https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A32022R0860.
Smith KW, White CM. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction. J Clin Pharmacol 2022;62(9):1079-1085.
Koskinas KC, Mach F, Räber L. Lipid-lowering therapy and percutaneous coronary interventions. EuroIntervention. 2021;16(17):1389-1403.
Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: A meta-Analysis. European Heart Journal 2022;43(34):3213-3223.
Oostindjer A, Roeters van Lennep JE. Bempedoinezuur, nieuwe lipidenverlagende medicatie. Ned Tijdschr Geneeskd. 2023;167:D7982.
Sinning D, Landmesser U. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Curr Cardiol Rep. 2020;22(12):176.
Nissen SE, Lincoff AM, Brennan D, et al; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-1364.
Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024;9(3):245-253.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet Lond Engl 1994;344:1383-1389.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. N Engl J Med 1995;333:1301-1308.
O’Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-2146.
Marcus FI, Baumgarten AJ, Fritz WL, et al. Alternate-day dosing with statins. Am J Med. 2013;126(2):99-104.
Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47(3):398-404.
Crandall JP, Mather K, Rajpathak SN, et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care 2017;5.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387-2397.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018;379:2097-2107.
O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146(15):1109-1119.
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012-1022.
VWS Staatscourant november 2023, 32601. Regeling van de Minister van Volksgezondheid, Welzijn en Sport van 21 november 2023, kenmerk 3721758-1056620-Z, houdende GVS regeling december 2023. https://zoek.officielebekendmakingen.nl/stcrt-2023-32601.html. Geraadpleegd april, 2024.
VWS Staatscourant december 2023, 35439. Regeling van de Minister van Volksgezondheid, Welzijn en Sport van 18 december 2023, kenmerk 3735742-1059270-GMT, houdende GVS regeling Januari. https://zoek.officielebekendmakingen.nl/stcrt-2023-35439.html. Geraadpleegd april, 2024.
Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69-76.
Universitair Medisch Centrum Utrecht. U-Prevent. https://www.u-prevent.nl. Geraadpleegd april, 2024.
SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42(25):2455-2467.
Armitage J, Baigent C, Barnes E, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet 2019;393:407-415.
Eilat‐Tsanani S, Mor E, Schonmann Y. Statin Use Over 65 Years of Age and All-Cause Mortality: A 10-Year Follow-Up of 19 518 People. J Am Geriatr Soc 2019;67:2038-2044.
Holmes HM, Min LC, Yee M, et al. Rationalizing prescribing for older patients with multimorbidity: Considering time to benefit. Drugs Aging 2013;30:655-666.